Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
Sponsored by The Cooper Health System
About this study
The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are: Does using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life? Participants will: Use an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake. Continue using the spirometer daily during treatment and for up to three months after treatment. Complete quality of life assessments at the start of the study and at 3, 6, and 12 months. Researchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\' well-being during and after their cancer treatment.
The INSPIRE-LUNG-CRT trial is a prospective, pilot study investigating the efficacy of incentive spirometry on the incidence and severity of pneumonitis in lung cancer patients undergoing concurrent chemotherapy and radiation therapy with immunotherapy maintenance. Despite advancements in treatment modalities, pulmonary complications remain a significant challenge, often leading to diminished functional capacity and quality of life. The trial aims to establish incentive spirometry as a non-pharmacological intervention to reduce these complications, thereby improving clinical outcomes and patient well-being. Lung cancer treatments are frequently associated with pulmonary toxicities, such as radiation-induced pneumonitis and fibrosis, immunotherapy induced pneumonitis, significantly impactin…
Where this study is enrolling
- I'm interested
MD Anderson Cancer Center at Cooper
Camden, New Jersey
Who can participate
Inclusion criteria
- ✓Confirmed diagnosis of advanced non-small-cell lung cancer
- ✓Performance status (ECOG 0-1)
- ✓Eligible for concurrent chemotherapy and radiation
- ✓18 years or older
Exclusion criteria
- ✕Previous lung or thoracic surgery
- ✕Enrollment in another pulmonary intervention trial
- ✕Home oxygen usage prior to enrolment
- ✕Radiological evidence of pleural effusion, pneumothorax, bullous emphysema, - or pneumonitis on staging imaging
- ✕Presence of active respiratory tract infection
- ✕Uncontrolled nausea and vomiting
- ✕Prior exposure to drugs such as amiodarone, bleomycin, or immunotherapy
- ✕Inability or unwillingness of individual to give written informed consent
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.